-
3 weeks ago | 
healio.com | Regina Schaffer |Katie Kalvaitis |Keith C. Ferdinand |Luke J. Laffin
Novel agent targeting aldosterone lowers blood pressure for adults with resistant hypertension• A dose-escalation strategy did not result in greater BP lowering. CHICAGO — The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, uncontrolled and “true” treatment-resistant hypertension, according to data from a new phase 2b study.
-
Nov 17, 2024 | 
healio.com | Regina Schaffer |Richard Smith |Keith C. Ferdinand |Dorairaj Prabhakaran
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA One of the interesting things about this study is the investigators used already approved and already effective BP medications, but in combinations to see which of those combinations would be most beneficial for BP reduction.
-
Oct 17, 2024 | 
healio.com | Scott Buzby |Erik Swain |Keith C. Ferdinand |Christie M. Ballantyne
You've successfully added CHD/Prevention to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Speakers highlighted recent regulatory moves in the areas of hypertension, lipids and diabetes.
-
Sep 21, 2024 | 
healio.com | Richard Smith |George Bakris |Keith C. Ferdinand
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The annual Cardiometabolic Health Congress will be held in October in Boston. Attendees will hear the latest on trending topics in cardiorenal and cardiometabolic health. For nearly 2 decades, George L.
-
Jun 19, 2024 | 
healio.com | Erik Swain |Richard Smith |Keith C. Ferdinand |Harlan M. Krumholz
Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLAUnfortunately, the data released in the JACC report are not new, but confirm the longstanding unfortunate and unacceptable disparities in CV morbidity and mortality across race/ethnicity that we see in the United States. The white/Black mortality gap was described 20 years ago by the Institute of Medicine and has been persistent, mainly driven by CVD. What is the solution? It will not be easy.
-
Apr 8, 2024 | 
healio.com | Regina Schaffer |Katie Kalvaitis |Keith C. Ferdinand |David Kandzari
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Alcohol-mediated renal nerve denervation is a novel strategy for people with uncontrolled and treatment-resistant hypertension. There was a large placebo effect seen in the sham group.
-
Dec 5, 2023 | 
nature.com | Keith C. Ferdinand
Racial and ethnic disparities in cardiovascular health in the USA result in a persistent mortality gap between white and Black individuals, increase health-care costs and compromise an egalitarian society. Solutions to racial inequities require risk factor control and the implementation of evidence-based medicine and anti-racism policies. Overcoming these disparities is not only a practical necessity, but also a moral imperative.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: I’m going to give each of you about a minute or so to give what we call a take-home message: a clinical pearl for the physicians, nurse practitioners, physician assistants, [and] pharmacists who may be listening, something that will motivate them to do better. We’ve heard from the Family Heart Foundation that we’re not recognizing these patients early enough and that those patients at high risk are not getting high-intensity statin.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Christie, where are we going with lipoprotein(a) [Lp(a)]? Have we reached the end of the road, or is there something on the horizon? Christie M. Ballantyne, MD, FACC: We’re just moving, and I agree with my colleagues. I screen everybody in my personal practice. I also do cascade screening. One thing we didn’t mention but I think is very important is if you’re looking at Black individuals, [they have] the highest levels of Lp(a), and it is a risk factor.
-
Nov 27, 2023 | 
hcplive.com | Keith C. Ferdinand |Erin D. Michos |Christie M. Ballantyne |Mary McGowan |Payal Kohli
Keith C. Ferdinand, MD, FACC, FAHA, FNLA: Dr [Payal] Kohli[, MD, FACC], the PCSK9 inhibitors were [addressed], and I know you’ve looked at some of the more recent data. They’ve been around a long time, and we now have data that [show] they really do work, and…for a long period…. Do you want to discuss that? Payal Kohli, MD, FACC: That’s right.
